Investor Hub

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases.

Latest investor presentation
Latest clinical presentation
Latest quarterly earnings
Annual report
Global ticker
NASDAQNVAX
Stock details
Loading data...
Stock Chart
NASDAQNVAX

Historical stock price

Select the date below for the historical closing price for that particular day.

The closing price is not indicative of future price performance.  Historical Stock Prices are provided for informational purposes only and are not intended for trading purposes.

NASDAQNVAX

Select A Date

Analyst coverage
Mayank Mamtani
B. Riley FBR
Alec Stranahan, PhD
BofA Securities
Georgi Yordanov, PhD
Cowen
Vernon Bernardino
H.C. Wainwright & Co.
Roger Song, MD, CFA
Jefferies
Eric Joseph, PhD
JP Morgan

The analysts listed on this page follow Novavax. Please note that any opinions, estimates or forecasts regarding Novavax' performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Novavax or its management. Novavax does not by its reference above or distribution imply its endorsements of or concurrence with such information, conclusions or recommendations.

Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription 

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at ir@novavax.com

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.